Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Lyell reports strong response rates for ronde-cel, but commercialisation remains years away.

What the company is saying

Lyell Immunopharma is highlighting positive updated clinical data for its lead CAR T-cell therapy candidate, ronde-cel, in relapsed/refractory large B-cell lymphoma. The company emphasises high complete response rates and durable remissions in both third- or later-line and second-line settings, with specific figures such as a 91% overall response rate and 77% complete response rate in 3L+ patients, and a 95% overall response rate and 76% complete response rate in 2L patients. The narrative stresses regulatory momentum, citing RMAT and Fast Track designations from the FDA, and positions the upcoming ASH 2026 conference as a key milestone for further data disclosure. Manufacturing capability is framed as a future strength, with LyFE expected to produce over 3,000 CAR T-cell doses per year, though this is presented as an expectation rather than a current reality. The tone is confident and forward-looking, with executive commentary from Chief Medical Officer Jarrad Aguirre, M.D., reinforcing belief in ronde-cel’s potential to improve patient outcomes. The announcement is structured to build credibility through detailed clinical metrics while projecting readiness for eventual commercial launch.

What the data suggests

The disclosed clinical data show high response rates for ronde-cel in both pivotal trials. In the 3L+ setting, 58 patients were treated, with a median age of 64, 50% having primary refractory disease, and 64% refractory to their last therapy. Among 44 response-evaluable patients at Day 84, the overall response rate was 91% and the complete response rate was 77%. Of those with a complete response, 92% remained in remission at six months and 75% at 12 months. Estimated progression-free survival rates were 76% at six months, 63% at 12 months, and 54% at 24 months, with a median PFS follow-up of 12 months. Safety data show no Grade ≥ 3 cytokine release syndrome, with Grade 1 CRS in 48% and Grade 2 in 22%, and Grade ≥ 3 ICANS in 9%. In the 2L cohort, 43 patients were treated, 86% with primary refractory disease; among 37 response-evaluable patients at Day 84, the overall response rate was 95% and the complete response rate was 76%. Of complete responders, 92% remained in remission at six months and 67% at 12 months. Estimated PFS rates were 75% at six months and 55% at 12 months, with a median follow-up of nine months. No Grade ≥ 3 CRS was observed; Grade 1 CRS occurred in 49% and Grade 2 in 19%, with Grade ≥ 3 ICANS in 9%. The data are robust for a late-stage clinical program, but all manufacturing and commercial readiness claims remain forward-looking, with no evidence of current commercial output or revenue.

Analysis

The announcement provides robust and specific clinical data from ongoing pivotal trials, including response rates, safety outcomes, and follow-up durations, which are all realised and well-supported. However, the most material forward-looking claims—namely, the expectation of full pivotal data in mid-2027, a BLA submission in the second half of 2027, and anticipated manufacturing capacity—are not yet realised and are at least 18-24 months away. The statement about LyFE's manufacturing capacity is aspirational, with no evidence of current output or operational readiness. There is a clear gap between the positive tone regarding future commercial readiness and the actual stage of development, as no product is approved or generating revenue, and no financial or cost data is disclosed. The capital intensity flag is triggered by the mention of large-scale manufacturing capability, but with no immediate earnings impact or operational output. Overall, while the clinical progress is credible, the narrative around commercial readiness and scale is somewhat inflated relative to current evidence.

Risk flags

• ●Execution risk is high due to the long timeline before pivotal data readout and regulatory submission, with full PiNACLE trial results and BLA submission not expected until mid-to-late 2027. Delays or negative data updates could materially impact the program’s prospects.
• ●Commercial and operational risk remains, as the stated manufacturing capacity of over 3,000 CAR T-cell doses per year is only an expectation; no evidence of current operational output or validated commercial supply chain is provided.
• ●Financial risk is present, as the announcement omits any discussion of cash position, burn rate, or funding runway, despite the capital-intensive nature of late-stage cell therapy development and manufacturing scale-up.
• ●Regulatory risk is inherent, as approval is contingent on future trial outcomes and successful submission; RMAT and Fast Track designations facilitate review but do not guarantee approval or market access.
• ●Competitive risk is significant, given that ronde-cel is being compared to existing approved CD19 CAR T-cell therapies in the PiNACLE-H2H trial, and any failure to demonstrate clear superiority could limit commercial uptake.

Bottom line

Lyell’s latest update confirms strong clinical activity and durability for ronde-cel in heavily pretreated large B-cell lymphoma patients, with response rates and progression-free survival figures that compare favorably to existing therapies. Safety data are acceptable, with no severe cytokine release syndrome and manageable neurotoxicity rates. However, all commercialisation milestones remain long-dated, with no product approval or revenue expected before late 2027. The company’s manufacturing scale is still aspirational, and there is no evidence of current commercial output or financial detail to assess funding sufficiency. Investors should focus on the upcoming ASH 2026 data update and watch for any changes in trial timelines, regulatory feedback, or manufacturing progress. The most important takeaway is that while clinical progress is real and promising, value realisation is at least 18–24 months away and subject to substantial execution and regulatory risk.

Announcement summary

(NASDAQ:LYEL) Lyell Immunopharma, Inc. announced that two abstracts featuring updated clinical data for rondecabtagene autoleucel (ronde-cel) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, scheduled for December 12–15, 2026. Ronde-cel is a dual-targeting CD19/CD20 autologous CAR T-cell product candidate being evaluated in two pivotal trials: PiNACLE, a single-arm trial in third- or later-line (3L+) large B-cell lymphoma (LBCL), and PiNACLE-H2H, a Phase 3 randomized controlled trial in the second-line (2L) setting. Ronde-cel has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. FDA for R/R diffuse LBCL in the 3L+ setting, and RMAT designation for LBCL in the 2L setting. As of June 18, 2026, 58 patients received ronde-cel in the 3L+ setting; the median age was 64 years, approximately 50% had primary refractory disease, and 64% were refractory to their last therapy. Of 44 response-evaluable patients at Day 84, the overall response rate was 91% and the complete response rate was 77%. Among patients with a complete response, 92% remained in complete response at six months and 75% at 12 months. Estimated progression-free survival (PFS) rates were 76% at six months, 63% at 12 months, and 54% at 24 months, with a median PFS follow-up of 12 months. No Grade ≥ 3 cytokine release syndrome (CRS) was observed; Grade 1 CRS occurred in 48% and Grade 2 in 22% of patients. Grade ≥ 3 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 9% of patients. In the fully enrolled Phase 1/2 second-line cohort, 43 patients received ronde-cel, including 86% with primary refractory disease. Among 37 response-evaluable patients at Day 84, the overall response rate was 95% and the complete response rate was 76%. Among patients with a complete response, 92% remained in complete response at six months and 67% at 12 months. Estimated PFS rates were 75% at six months and 55% at 12 months, with a median PFS follow-up of nine months. No Grade ≥ 3 CRS was observed; Grade 1 CRS occurred in 49% and Grade 2 in 19% of patients. Grade ≥ 3 ICANS occurred in 9% of patients. Ronde-cel is also being evaluated in the ongoing PiNACLE-H2H Phase 3 trial in the 2L setting. Full pivotal data from the PiNACLE trial are expected in mid-2027, with a BLA submission expected in the second half of 2027. LyFE, Lyell's manufacturing platform, is expected to have the capacity to manufacture more than 3,000 CAR T-cell doses per year.

Disagree with this article?